Literature DB >> 2899908

HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor.

G P Linette1, R J Hartzman, J A Ledbetter, C H June.   

Abstract

The binding of antigen or monoclonal antibody to the T cell receptor for antigen or the closely associated CD3 complex causes increases in the concentration of intracellular ionized calcium and subsequent cell proliferation. By measuring second messenger production in primary cultures of human immunodeficiency virus (HIV-1)--infected T cells stimulated with monoclonal antibodies specific for either CD3 or CD2, a specific impairment of membrane signaling was revealed. The HIV-1--infected T cells were unable to mobilize Ca2+ after stimulation with anti-CD3, whereas CD2-induced calcium mobilization remained intact. Furthermore, the HIV-1--infected cells proliferated poorly after CD3 stimulation, although the cells retained normal DNA synthesis in response to interleukin-2 stimulation. These results show that the signals initiated by CD2 and CD3 can be regulated independently within the same T cell; uncoupling of signal transduction after antigen-specific stimulation provides a biochemical mechanism to explain, in part, the profound immunodeficiency of patients with HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899908     DOI: 10.1126/science.2899908

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  25 in total

1.  Failure of T cell receptor-anti-CD3 monoclonal antibody interaction in T cells from marrow recipients to induce increases in intracellular ionized calcium.

Authors:  M Yamagami; P W McFadden; S M Koethe; V Ratanatharathorn; L G Lum
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

2.  Toward synthetic biology with engineered T cells: a long journey just begun.

Authors:  Carl H June
Journal:  Hum Gene Ther       Date:  2014-09       Impact factor: 5.695

3.  Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein.

Authors:  S B Tencza; M A Miller; K Islam; T A Mietzner; R C Montelaro
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

Review 4.  Modulation of T cell proliferative response by accessory cell interactions.

Authors:  J M Green; C B Thompson
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

5.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Induction of apoptosis in a T lymphoblastoid cell line infected with feline immunodeficiency virus.

Authors:  K Ohno; Y Okamoto; T Miyazawa; T Mikami; T Watari; R Goitsuka; H Tsujimoto; A Hasegawa
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

7.  Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection.

Authors:  M Timón; A Arnaiz-Villena; J Ruiz-Contreras; J T Ramos-Amador; A Pacheco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Costimulation of T-cell activation and virus production by B7 antigen on activated CD4+ T cells from human immunodeficiency virus type 1-infected donors.

Authors:  O K Haffar; M D Smithgall; J Bradshaw; B Brady; N K Damle; P S Linsley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.

Authors:  A Ammar; Y Sahraoui; A Tsapis; A M Bertoli; C Jasmin; V Georgoulias
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.